Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $50,588.43 in Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 14,331 shares of Genelux stock in a transaction on Monday, April 22nd. The shares were sold at an average price of $3.53, for a total value of $50,588.43. Following the completion of the transaction, the insider now owns 1,285,794 shares of the company’s stock, valued at approximately $4,538,852.82. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Wednesday, April 24th, Aladar Szalay sold 8,064 shares of Genelux stock. The shares were sold at an average price of $3.50, for a total value of $28,224.00.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Price Performance

NASDAQ GNLX traded down $0.03 during midday trading on Wednesday, hitting $3.45. The company had a trading volume of 137,205 shares, compared to its average volume of 125,442. The firm has a 50-day moving average price of $5.95 and a 200-day moving average price of $11.00. Genelux Co. has a twelve month low of $3.26 and a twelve month high of $40.98.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings data on Friday, March 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). As a group, equities analysts predict that Genelux Co. will post -0.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

GNLX has been the subject of a number of research analyst reports. Benchmark reissued a “speculative buy” rating and issued a $30.00 target price on shares of Genelux in a research note on Wednesday, April 3rd. HC Wainwright dropped their price objective on Genelux from $35.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, April 2nd.

Institutional Investors Weigh In On Genelux

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Genelux by 1,660.1% in the 3rd quarter. Vanguard Group Inc. now owns 980,993 shares of the company’s stock valued at $24,025,000 after buying an additional 925,258 shares during the last quarter. D.A. Davidson & CO. bought a new stake in Genelux during the 3rd quarter worth approximately $237,000. Advisor Resource Council bought a new position in Genelux during the fourth quarter valued at $233,000. Barclays PLC grew its holdings in Genelux by 516.4% during the third quarter. Barclays PLC now owns 3,384 shares of the company’s stock valued at $83,000 after purchasing an additional 2,835 shares during the period. Finally, Whittier Trust Co. purchased a new stake in shares of Genelux during the third quarter worth $175,000. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.